GlassScriptPhysician profile
Norman Lepor
NPI 1013979673
$1,883,992.51
in general payments reported to CMS, 2019-2025
65 companies · $171K in 2025
The $171K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $493K · 2020: $140K · 2021: $316K · 2022: $329K · 2023: $155K · 2024: $279K · 2025: $171K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $402K · Consulting Fee: $74K · Travel and Lodging: $63K · Honoraria: $44K · Food and Beverage: $23K · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $402,480.94 |
| Consulting Fee | $73,791.20 |
| Travel and Lodging | $62,547.05 |
| Honoraria | $43,680.00 |
| Food and Beverage | $23,258.70 |
| Education | $130.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $238,492.74 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $201,039.86 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $192,450.38 | 2019-2025 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $178,254.72 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $157,205.04 | 2019-2023 | |
| Novo Nordisk INC | $132,587.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $107,308.97 | 2020-2022 | |
| Amarin Pharma, INC. | $106,428.57 | 2019 | |
| Amgen INC. | $94,600.62 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $94,517.99 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Novartis Pharmaceuticals Corporation | $89,121.76 | 2019-2025 | Leqvio |
| Regeneron Healthcare Solutions, INC. | $75,683.43 | 2019-2025 | Evkeeza, Praluent, Dupixent |
| Lexicon Pharmaceuticals, INC. | $51,909.29 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $48,197.32 | 2021-2023 | Arcalyst |
| Regeneron Pharmaceuticals, INC. | $24,014.32 | 2019-2025 | Evkeeza |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20,100.37 | 2021-2025 | Korlym |
| Eli Lilly and Company | $17,172.21 | 2020-2024 | |
| Vifor Pharma, INC. | $13,317.79 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $10,131.19 | 2025 | Olezarsen, Tryngolza |
| E.R. Squibb & Sons, L.L.C. | $7,469.96 | 2019-2025 | Eliquis, Camzyos |
| Agepha Pharma Fz LLC | $4,422.21 | 2024-2025 | Lodoco |
| Idorsia Pharmaceuticals US INC | $3,540.00 | 2024 | Tryvio |
| Daiichi Sankyo INC. | $3,425.33 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $2,631.64 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $2,130.43 | 2025 | Attruby |
| Medtronic Vascular, INC. | $1,786.64 | 2019-2020 | |
| Pfizer INC. | $1,058.80 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $728.84 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $720.69 | 2021-2025 | Amvuttra |
| Medtronic, INC. | $718.13 | 2021-2023 | Reveal Linq, Linq II |
| Abbott Laboratories | $388.67 | 2021-2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $376.20 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman Access System |
| Edwards Lifesciences Corporation | $249.51 | 2020-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharma Ag | $186.95 | 2019 | |
| Currax Pharmaceuticals LLC | $169.10 | 2019-2025 | Contrave |
| Kestra Medical Technology Services, INC. | $153.15 | 2022-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $135.02 | 2025 | |
| Eisai INC. | $129.61 | 2019-2021 | |
| Biosense Webster, INC. | $125.17 | 2022 | |
| Heartflow, INC. | $122.50 | 2022-2025 | Ffrct |
| Arbor Pharmaceuticals, INC. | $119.23 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $110.23 | 2023 | Optimizer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.28 | 2023-2024 | Xifaxan |
| Actelion Pharmaceuticals US, INC. | $85.22 | 2019-2023 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $70.26 | 2021-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $49.03 | 2021 | |
| Astrazeneca Ab | $40.18 | 2022 | |
| Medicure Pharma INC. | $36.21 | 2021-2022 | |
| Bsn Medical INC | $34.78 | 2022 | |
| Philips North America LLC | $25.00 | 2025 | Vest Therapy Und |
| Aegerion Pharmaceuticals, INC. | $23.01 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.16 | 2023 | Jynarque |
| Vivus LLC | $21.33 | 2023 | Qsymia |
| Amryt Pharma Holdings LTD | $14.72 | 2021 | |
| Baxter Healthcare | $13.13 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Venclose INC. | $11.99 | 2020 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$145,689.36 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Lepor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.